{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
methylene blue
to a specific field?
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
GSK-9089 (also known as DY131, N-(4-(Diethylaminobenzylidenyl)-N'-(4-hydroxy benzoyl)-hydrazine) is a novel selective agonist at estrogen-related receptors ERRβ and ERRγ, that displays minimal activity at ERRα, ERα and ERβ at concentrations up to 30 μM. DY131 inhibits growth in a diverse panel of prostate and breast cancer cell lines, causing cell death that involves the p38 stress kinase pathway and a bimodal cell cycle arrest.
Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)
BAY-36-7620 is a potent and selective antagonist at mGlu1receptors and inhibits >60% of mGlu1a receptor constitutive activity (IC50 = 0.38 uM). BAY-36-7620 is thus the first described mGlu1 receptor inverse agonist. It impairs classical conditioning and associated synaptic plasticity in hippocampal neurons. BAY-36-7620 exhibits neuroprotective and anticonvulsive effects in vivo following systemic administration.
![Structure of 5-[(2-Chlorobenzylidene)amino]isoquinoline](/img/aadd22b9-eb62-4e78-b4e2-f75668d726f6.svg?size=200&context=bhimdnuoah)
